ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 97,500 shares of the company’s stock after selling 2,250 shares during the period. Victory Capital Management Inc. owned 0.14% of ORIC Pharmaceuticals worth $787,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its holdings in ORIC Pharmaceuticals by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company’s stock worth $121,000 after buying an additional 1,395 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in ORIC Pharmaceuticals during the 3rd quarter worth about $132,000. Intech Investment Management LLC purchased a new stake in ORIC Pharmaceuticals during the 3rd quarter worth about $200,000. JPMorgan Chase & Co. lifted its holdings in ORIC Pharmaceuticals by 3.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company’s stock worth $361,000 after buying an additional 1,279 shares during the last quarter. Finally, Verition Fund Management LLC lifted its holdings in ORIC Pharmaceuticals by 25.6% during the 3rd quarter. Verition Fund Management LLC now owns 42,980 shares of the company’s stock worth $441,000 after buying an additional 8,752 shares during the last quarter. 95.05% of the stock is owned by hedge funds and other institutional investors.

ORIC Pharmaceuticals Stock Up 0.5 %

ORIC opened at $7.51 on Friday. The business has a 50 day moving average price of $9.09 and a two-hundred day moving average price of $9.26. The company has a market cap of $533.41 million, a PE ratio of -4.13 and a beta of 1.25. ORIC Pharmaceuticals, Inc. has a 52 week low of $6.33 and a 52 week high of $15.35.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.01. As a group, sell-side analysts expect that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Wedbush reissued an “outperform” rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a report on Thursday. Guggenheim reissued a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $18.86.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.